This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin sessions to receive either a full dose (30mg or 40mg) or low dose (10mg or 15mg).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percent Heavy Drinking Days
Timeframe: Weeks 0-24 following the first psilocybin dosing session.
Adverse effects
Timeframe: 1, 2, 4, 8, 16, 24 and 48 weeks after receiving the second dose of the psilocybin treatment.
Cue-Induced Craving Response
Timeframe: Measured at baseline, 4 and 24 weeks after the second psilocybin treatment.
Neural Response and Connectivity Changes measured by fMRI
Timeframe: 1 week before and 1 week after the second psilocybin session
Neural Response and Connectivity Changes measured by fMRI
Timeframe: 1 week before and 1 week after the second psilocybin session
Neural Response and Connectivity Changes measured by fMRI
Timeframe: 1 week before and 1 week after the second psilocybin session